Anumana Entered into a Multi-Year Strategic Collaboration with Novartis to Develop ECG AI Algorithms for the Detection of Heart Disease
Shots:
- The companies collaborated to develop & deliver new medical device software i.e., ECG AI algorithms for earlier detection of heart disease
- The AI will screen for atherosclerotic CV disease which can cause a heart attack or stroke. An evidence-based, digital point-of-care system will be created in order to improve medical therapies & lower the risk of hospitalizations and CV death
- Each algorithm for these software solutions is currently in development as a candidate for marketing authorization through an FDA De Novo request. In a recent study presented by Mayo Clinic, single-lead ECGs from smartwatches were used to diagnose LV dysfunction using a modified version of Anumana's 12-lead ECG algorithm
Ref: Bussinesswire | Image: Anumana
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
